149 related articles for article (PubMed ID: 17722224)
1. Rituximab for refractory polymyositis: an open-label prospective study.
Mok CC; Ho LY; To CH
J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224
[TBL] [Abstract][Full Text] [Related]
2. Rituximab treatment in patients with refractory inflammatory myopathies.
Mahler EA; Blom M; Voermans NC; van Engelen BG; van Riel PL; Vonk MC
Rheumatology (Oxford); 2011 Dec; 50(12):2206-13. PubMed ID: 21571768
[TBL] [Abstract][Full Text] [Related]
3. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate.
Hengstman GJ; De Bleecker JL; Feist E; Vissing J; Denton CP; Manoussakis MN; Slott Jensen H; van Engelen BG; van den Hoogen FH
Eur Neurol; 2008; 59(3-4):159-63. PubMed ID: 18230873
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of dermatomyositis: an open-label pilot study.
Levine TD
Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974
[TBL] [Abstract][Full Text] [Related]
5. A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L; Genovese MC; Fiorentino DF
Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943
[TBL] [Abstract][Full Text] [Related]
6. A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.
Adams EM; Pucino F; Yarboro C; Hicks JE; Thornton B; McGarvey C; Sonies BC; Bartlett ML; Villalba ML; Fleisher T; Plotz PH
J Rheumatol; 1999 Feb; 26(2):352-60. PubMed ID: 9972969
[TBL] [Abstract][Full Text] [Related]
7. Rituximab as therapy for refractory polymyositis and dermatomyositis.
Noss EH; Hausner-Sypek DL; Weinblatt ME
J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome.
Johnson RW; Williams FM; Kazi S; Dimachkie MM; Reveille JD
Arthritis Rheum; 2003 Apr; 49(2):172-8. PubMed ID: 12687507
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
[TBL] [Abstract][Full Text] [Related]
10. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
11. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.
Sem M; Molberg O; Lund MB; Gran JT
Rheumatology (Oxford); 2009 Aug; 48(8):968-71. PubMed ID: 19531628
[TBL] [Abstract][Full Text] [Related]
12. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
13. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
Dass S; Bowman SJ; Vital EM; Ikeda K; Pease CT; Hamburger J; Richards A; Rauz S; Emery P
Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
[TBL] [Abstract][Full Text] [Related]
14. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients.
Flint-Wagner HG; Lisse J; Lohman TG; Going SB; Guido T; Cussler E; Gates D; Yocum DE
J Clin Rheumatol; 2009 Jun; 15(4):165-71. PubMed ID: 19279507
[TBL] [Abstract][Full Text] [Related]
15. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
[TBL] [Abstract][Full Text] [Related]
16. Effects of rituximab on resistant SLE disease including lung involvement.
Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
[TBL] [Abstract][Full Text] [Related]
17. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case].
Yáñez V J; Cisternas M M; Saldías H V; Saldías P F
Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327
[TBL] [Abstract][Full Text] [Related]
18. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rituximab in refractory polymyositis.
Lambotte O; Kotb R; Maigne G; Blanc FX; Goujard C; Delfraissy JF
J Rheumatol; 2005 Jul; 32(7):1369-70. PubMed ID: 15996082
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Ewals JA; Han KH; Hazes JM; Kerstens PJ; Peeters AJ; van Zeben D; Breedveld FC; Huizinga TW; Dijkmans BA; Allaart CF
Arthritis Rheum; 2009 Jan; 61(1):4-12. PubMed ID: 19116965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
